Iovance hits two-year high after raising annual revenue forecast

By Reuters News

** Shares of Iovance Biotherapeutics IOVA.O rise 27.5% to $14, their highest level in more than two years

** Co raises FY26 revenue outlook to $410 mln-$420 mln, from a prior forecast of $350 mln-$370 mln

** "Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint," CEO says

** 8 of 10 brokerages rate the stock "buy" or higher and two "hold"; median PT is $11 — data compiled by LSEG

** Including session's move, stock has jumped more than five times in value YTD

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk